Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity

Science. 2023 Mar 17;379(6637):eabg2482. doi: 10.1126/science.abg2482. Epub 2023 Mar 17.

Abstract

Autoimmune diseases such as ankylosing spondylitis (AS) can be driven by emerging neoantigens that disrupt immune tolerance. Here, we developed a workflow to profile posttranslational modifications involved in neoantigen formation. Using mass spectrometry, we identified a panel of cysteine residues differentially modified by carboxyethylation that required 3-hydroxypropionic acid to generate neoantigens in patients with AS. The lysosomal degradation of integrin αIIb [ITGA2B (CD41)] carboxyethylated at Cys96 (ITGA2B-ceC96) generated carboxyethylated peptides that were presented by HLA-DRB1*04 to stimulate CD4+ T cell responses and induce autoantibody production. Immunization of HLA-DR4 transgenic mice with the ITGA2B-ceC96 peptide promoted colitis and vertebral bone erosion. Thus, metabolite-induced cysteine carboxyethylation can give rise to pathogenic neoantigens that lead to autoreactive CD4+ T cell responses and autoantibody production in autoimmune diseases.

MeSH terms

  • Animals
  • Autoantibodies* / metabolism
  • Autoimmune Diseases* / genetics
  • Autoimmune Diseases* / metabolism
  • Autoimmunity / genetics
  • Autoimmunity / immunology
  • Cysteine* / metabolism
  • Gastrointestinal Microbiome
  • HLA-DRB1 Chains* / genetics
  • HLA-DRB1 Chains* / metabolism
  • Humans
  • Integrin alpha2* / metabolism
  • Mice
  • Mice, Transgenic
  • Protein Processing, Post-Translational*
  • Spondylitis, Ankylosing* / genetics
  • Spondylitis, Ankylosing* / metabolism

Substances

  • Autoantibodies
  • Cysteine
  • HLA-DRB1 Chains
  • Integrin alpha2
  • 3-hydroxypropionaldehyde